Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
Fund managers haven’t disclosed any holdings of IBER.U yet.
IBER.U Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q1 2023, worth a combined $0 — down 100% from $4.01M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IBER.U and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Schechter Investment Advisors, exiting entirely with an estimated $1.75M sold.
- 0 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q1 2023, down from 10 in Q4 2022.
- Funds reported $0 of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q1 2023 and 10 closed out, a net change of -10 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q1 2023 was Schechter Investment Advisors, an estimated $1.75M sold.
Based on aggregated 13F filings for Q1 2023.